



**Sponsors**



## 26<sup>th</sup> Annual Cancer Progress Conference March 17-18, 2015 New York

### Tuesday, March 17, 2015

**7:00 – 8:00am**                      **Registration and Continental Breakfast**

**8:00 – 8:15am**                      **Opening Remarks**

Jeff Bockman, PhD, VP, Defined Health

**8:15 – 9:15am**                      **Plenary Keynote: Progress, at What Price?**

Moderator:

- Ed Saltzman, President, Defined Health

Panelists:

- Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
- Lee Newcomer, MD, MHA, SVP, Oncology, Genetics and Women's Health, United Healthcare
- Leonard Saltz, MD, Professor of Medicine, Weill Cornell Medical College; Chief, Gastrointestinal Oncology Service, Chair, Pharmacy and Therapeutics Committee, Memorial Sloan Kettering Cancer Center

**9:15 – 10:30am**                      **A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes**

Moderator:

- Otis Webb Brawley, MD, FACP, Chief Medical and Scientific Officer, Executive Vice President, Research, American Cancer Society

Panelists:

- Brad Gray, President & CEO, NanoString Technologies
- Amy Krie, MD, Medical Oncology and Hematology, Avera McKennan
- Manfred Lehnert, MD, VP and Head, Innovation, Oncology Therapeutic Area Unit, Takeda Pharmaceuticals International
- Brian Leyland-Jones, MB BS, PhD, VP, Molecular and Experimental Medicine, Avera McKennan
- John J. Sninsky, PhD, Chief Scientific Officer, CareDX

**10:30 – 10:45am**                      **Networking Break**



**10:45 – 12:00pm**

**Tumor Panel I: Rare and Pediatric Cancers**

Moderator:

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Peter C. Adamson, MD, Chair, Children's Oncology Group, Alan R. Cohen Endowed Chair in Pediatrics, The Children's Hospital of Philadelphia
- Meredith K. Chuk, MD, Scientific Liaison for Sarcoma, Medical Officer, FDA
- Carlos Rodriguez-Galindo, MD, Associate Professor, Department of Pediatrics, Harvard Medical School; Medical Director, Pediatric Oncology Clinical Trials, Pediatric Oncology, Dana-Farber Cancer Institute; Director, Solid Tumor Program, Pediatric Oncology, Dana-Farber Cancer Institute
- Peter Sandor, MD, MBA, Vice President, Global Marketing Oncology, Amgen
- Maoxia Zheng, PhD, Global Development Team Leader, Pediatric Oncology, Genentech

**12:00 – 1:15pm**

**Networking Luncheon**

**1:15 – 2:30pm**

**Immunotherapy I: Targeting Checkpoint, Co-Stimulatory and Novel Immunomodulatory MOAs**

Moderator:

- Jeff Bockman, PhD, VP, Defined Health

Panelists:

- Ada Braun, MD, PhD, Chief Medical Officer, Biothera
- Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
- Johanna Joyce, PhD, Member, Memorial Sloan Kettering Cancer Center
- Hy Levitsky, MD, Adjunct Professor, Oncology, Medicine and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Nils Lonberg, PhD, SVP, Biologics Discovery, Bristol-Myers Squibb
- Harlan Robins, PhD, Co-Founder and Chief Scientific Officer, Adaptive Biotechnologies
- Jedd Wolchok, MD, PhD, Ludwig Center at Memorial Sloan Kettering Cancer Center

**2:30 – 3:45pm**

**Immunotherapy II: Engineered Cell Therapy**

Moderator:

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Associate Attending Physician, Dept of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center
- Thomas J. Farrell, CEO, Bellicum Pharmaceuticals
- Prof. Dolores J. Schendel, PhD, Chief Scientific Officer, Medigene
- Gaurav Shah, MD, Global Clinical Program Head (CART / CTL019 Adoptive T-cell Therapies) Novartis Pharmaceuticals
- Cassian Yee, MD, Professor, Dept of Melanoma Medical Oncology, Professor, Dept of Immunology, Director, Solid Tumor Cell Therapy, MD Anderson Cancer Center

**3:45 – 4:00pm**

**Networking Break**



**4:00 – 5:15pm**

**Tumor Panel II: B-Cell Malignancies: Recent Advances, Remaining Challenges and Promising New Approaches**

Moderator:

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Omar Abdel-Wahab, MD, Hematologist/Oncologist, Memorial Sloan Kettering Cancer Center
- Stanley R. Frankel, MD, Adjunct Associate Professor of Medicine, Division of Hematology/Oncology, Columbia University College of Physicians and Surgeons
- William Grossman, MD, PhD, Therapeutic Area Lead, Oncology-Global Pharmaceutical R&D/Global Medical Affairs, AbbVie
- Thomas J. Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, Distinguished Professor & Deputy Director, Research Operations, UC San Diego Moores Cancer Center

**5:15 – 6:30pm**

**Combination Therapies: Challenges and Opportunities**

Moderator:

- Jeff Bockman, PhD, VP, Defined Health

Panelists:

- Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
- Ivan Horak, MD, Chief Scientific/Medical Officer, Symphogen A/S
- Noemi Rosa, Novartis
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics

**6:30 – 8:30pm**

**Cancer Progress 2015 Reception**

---



**Wednesday, March 18, 2015**

**7:00 – 8:00am Continental Breakfast**

**8:00 – 8:15am Opening Remarks**

Mike Rice, MS, MBA, Senior Consultant, Defined Health

**8:15 – 9:15am Keynote Address:  
Technology and Big Data: Transforming Cancer Research and Care**

- Lynda Chin, MD, Department Chair, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

**9:15 – 10:30am Bucket Trials and Drug Umbrellas**

Moderator:

- Haleh Saber, PhD, Principal Consultant, PAREXEL International

Panelists:

- James H. Doroshow, MD, Deputy Director for Clinical and Translational Research, National Cancer Institute
- Patricia LoRusso, DO, Associate Center Director of Innovative Medicine, Smilow Cancer Center, Yale University
- Ellen V. Sigal, PhD, Chairperson & Founder, Friends of Cancer Research
- Eric Slosberg, PhD, Senior Director, Translational Medicine, Early Development, Strategy & Innovation, Novartis Oncology
- Marc Theoret, MD, Scientific Liaison for Melanoma, Lead Medical Officer, Melanoma/Sarcoma Group, FDA

**10:30 – 10:45am Networking Break**

**10:45 – 12:00pm Moving Beyond Mutations to Key Drivers: From Sequence to Function to Decision**

Moderator:

- Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

- Robert Cohen, MD, Calico Life Sciences
- Christoph Lengauer, PhD, MBA, Chief Scientific Officer, Blueprint Medicines
- Ronnie Morris, MD, President, Champions Oncology
- Rob Ruijtenbeek, PhD, Chief Scientific Officer, PamGene BV
- Jeffrey Settleman, PhD, Senior Director, Discovery Oncology, Genentech

**12:00 – 1:15pm Networking Luncheon**



**1:15 – 2:30pm**

**Exceptional Responders**

Moderator:

- Robert H. Glassman, MD, Managing Director Global Healthcare Investment Banking, Merrill Lynch

Panelists:

- Barbara A. Conley, MD, Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
- Sean Ferree, PhD, Vice President, Diagnostic Development, NanoString Technologies
- Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center
- Cecilia Schott, PharmD, MBA, Head Personalized Healthcare, Corporate Business Development, AstraZeneca
- David Solit, MD, Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

**2:30 – 3:45pm**

**Funding and Conducting Cancer Research: New Paths Forward**

Moderator:

- Mark J. Simon, Advisor, Torrey Partners LLC

Panelists:

- Thomas O. Daniel, MD, Executive Vice President & President, Global Research and Early Development, Global Research, Celgene
- Louis J. DeGennaro, PhD, President & CEO, Leukemia & Lymphoma Society
- Kathleen A. Denis, PhD, CLP, AVP, Office of Technology Transfer, The Rockefeller University
- Louise M. Perkins, PhD, Chief Science Officer, Melanoma Research Alliance
- Nathan P. Sanburn, Director, Strategy and Business Development Oncology, Eli Lilly and Company

**3:45 – 4:00pm**

**Networking Break**

**4:00 – 5:15pm**

**Evolution of Cancer: New Ways of Thinking about an Old Scourge**

Moderator:

- Jean-Pierre Bizzari, MD, EVP, Clinical Research & Development, Celgene

Panelists:

- Robert A. Beckman, MD, Professor, Georgetown University; External Faculty, Center for Evolution and Cancer, University of California At San Francisco
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norma S. Sarofim Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center

**5:15pm**

**Closing Remarks**

**5:30pm**

**Cancer Progress 2015 Conference Concludes**